Targeted Temperature Management at 33°C Versus Controlled Normothermia for In-hospital Cardiac Arrest

Not Applicable

Not yet recruiting

• Conditions: Cardiac Arrest

• Registration Number: NCT07086703
• Lead Sponsor: Nantes University Hospital

Brief Summary

The IH-TTM trial is designed to determine whether survival with a favorable neurological outcome is improved by induced hypothermia at 33°C in comatose critically ill patients admitted after resuscitated in-hospital cardiac arrest (IHCA). Recent evidence suggests that targeted temperature management (TTM) at 33°C may provide no survival benefits compared to controlled normothermia in unselected patients with out-of-hospital cardiac arrest (OHCA). However, this evidence is relevant only to OHCA of presumed cardiac origin, chiefly witnessed and immediately followed by resuscitation efforts. Only scant data are available for cardiac arrest (CA) of other origins and for IHCA.

In a randomized clinical trial of patients with CA in an initial non-shockable rhythm, the subgroup with IHCA had significantly better outcomes when treated with TTM at 33°C versus controlled normothermia; nevertheless, the sample size was limited. Another randomized controlled trial done specifically in patients with IHCA failed to show benefits of TTM at 33°C compared to controlled normothermia but was underpowered. Thus, whether therapeutic hypothermia is indicated after IHCA remains unclear. IH-TTM will be the largest trial assessing TTM after IHCA.

Detailed Description

Not available

Study Timeline

• Status Verified: 2025-07
• Study First Submitted: 2025-07-18
• Study First Submitted QC: 2025-07-18
• Study First Posted: 2025-07-25
• Last Update Submitted: 2025-07-30
• Last Update Posted: 2025-08-03
• Study Start: 2025-12-01
• Primary Completion: 2029-05-01
• Study Completion: 2029-05-01

Recruitment & Eligibility

• Status: NOT_YET_RECRUITING
• Sex: All
• Target Recruitment: 788

Inclusion Criteria

• IHCA (unwitnessed IHCA with initial asystole; these patients may still be eligible if visible or audible signs of life were witnessed within 10 minutes after IHCA (no-flow duration ≤10 minutes, in keeping with the non-inclusion criteria for HYPERION study).
• Sustained ROSC (Return Of Spontaneous Circulation) defined as signs of circulation for 20 minutes without chest compressions
• At least 1 mg of epinephrine
• Coma defined as an inability to obey verbal commands (Glasgow Coma Scale motor response <6 or Full Outline of UnResponsiveness (FOUR) score motor response <4) after sustained ROSC
• Eligible for intensive care without restrictions or limitations
• Inclusion within 90 minutes of ROSC
• Age 18 years or older
• Next of kin informed about the trial and having consented to participation of the patient in the trial (patients with coma are unable to consent). If no next of kin can be contacted during screening for the study, trial inclusion will be completed as an emergency procedure by the ICU physician, in compliance with Country of inclusion law.
• Healthcare costs covered by the French statutory healthcare insurance system

Exclusion Criteria

• Temperature at admission <30°C
• Obvious or suspected pregnancy
• Intracranial bleeding
• Dependent on others for activities of daily living before hospitalization
• Patient under curators, guardianship or under protection of justice
• Correctional facility inmate
• Patient who does no speak French

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Primary Outcome Measures

Name	Time	Method
To assess whether induced hypothermia (TTM at 33°C) is superior to targeted normothermia in providing a favorable neurological outcome, defined as a modified Rankin Scale (mRS) score of 0 to 3 at 6 months.	6 months after randomization	The primary endpoint is a favorable neurological outcome at 6 months, defined as an mRS score between 0 and 3.

Secondary Outcome Measures

Name	Time	Method
All-cause mortality 2 months after randomization	2 months after randomization	Causes of death (refractory hemodynamic shock, life-support withdrawal for neurological reasons, life-support withdrawal due to comorbidities, respiratory failure, sudden cardiac death, brain death)
All-cause mortality 3 months after randomization	3 months after randomization	Causes of death (refractory hemodynamic shock, life-support withdrawal for neurological reasons, life-support withdrawal due to comorbidities, respiratory failure, sudden cardiac death, brain death)
All-cause mortality 4 months after randomization	4 months after randomization	Causes of death (refractory hemodynamic shock, life-support withdrawal for neurological reasons, life-support withdrawal due to comorbidities, respiratory failure, sudden cardiac death, brain death)
All-cause mortality 6 months after randomization	6 months after randomization	Causes of death (refractory hemodynamic shock, life-support withdrawal for neurological reasons, life-support withdrawal due to comorbidities, respiratory failure, sudden cardiac death, brain death)
ICU lengths of stay	from day of randomization until the day of discharge from ICU, an average of 20 days.
Hospital lengths stay	from day of randomization until the day of discharge from hospital, an average of 20 days.
Neurological outcome measured by modified Rankin Scale (mRS) score, ranging from 0 to 6 at 2 months after randomization	2 months after randomization
Neurological outcome measured by modified Rankin Scale (mRS) score, ranging from 0 to 6 at 3 months after randomization	3 months after randomization	A score of 0 to 3 is considered a favorable neurological outcome.
Neurological outcome measured by modified Rankin Scale (mRS) score ranging from 0 to 6 at 4 months after randomization	4 months after randomization	A score of 0 to 3 is considered a favorable neurological outcome.
Mechanical ventilation duration	from time of randomization to final extubation or up to 28 days	A score of 0 to 3 is considered a favorable neurological outcome.
Biomarkers concentration : neuron-specific enolase (NSE) on day 0	at day 0
Biomarkers concentration : neuron-specific enolase (NSE) on day 2	at day 2
Biomarkers concentration : neuron-specific enolase (NSE) on day 3	at day 3
Biomarkers concentration : neurofilament light chain (NFL) on day 2	at day 2
Health-related quality of life (HRQoL) assessed using the 36-item Short Form Health Survey (SF-36) 6 months after randomization	6 months after randomization
Cognitive dysfunction assessed using the Montreal Cognitive Assessment (MoCA) 6 months after randomization	6 months after randomization
Complications during ICU stay : nosocomial infections	from day of randomization until the day of discharge from ICU, or up to 28 days.
Complications during ICU stay : severe arrhythmias	from day of randomization until the day of discharge from ICU, or up to 28 days.
Complications during ICU stay : venous thromboembolism	from day of randomization until the day of discharge from ICU, or up to 28 days.
Complications during ICU stay : ischemic complications	from day of randomization until the day of discharge from ICU, or up to 28 days.
Complications during ICU stay : sedations complications	from day of randomization until the day of discharge from ICU, or up to 28 days.

Trial Locations

Locations (32)

CHU de Nantes; 🇫🇷 Nantes, France

Hôpital Erasme; 🇧🇪 Bruxelles, Belgium

CHU Charleroi; 🇧🇪 Charleroi, Belgium

Hôpital Universitaire de Gand; 🇧🇪 Gand, Belgium

Hôpital Universitaire de Bruxelles; 🇧🇪 Jette, Belgium

Clinique Saint-PIerre; 🇧🇪 Ottignies, Belgium

CH d'Angoulême; 🇫🇷 Angoulême, France

CH Dubois Brive; 🇫🇷 Brive-la-Gaillarde, France

CHU de Caen; 🇫🇷 Caen, France

Hôpital Simone Veil; 🇫🇷 Cannes, France

Scroll for more (22 remaining)